Relevant Interviews, Webinar and Trial Updates posted by CRISPR Medicine News.

Always stay updated with the free CMN Newsletter.

Arbor Biotechnologies

Main focus: Gene therapies and gene editing for the treatment of genetic diseases

Company stage: Pre-clinical

Diseases (gene editing): Primary Hyperoxaluria, undisclosed liver diseases

Genome editing tool: CRISPR-Cas13d, multiple novel CRISPR variants

Funding stage: Private

Location: Cambridge, MA, USA



Gene editing partnerships: Vertex Pharmaceuticals, Vor Biopharma

Arbor Biotechnologies is a CRISPR-focused company that develops novel Cas variants for enhanced precision and efficacy. The company's lead programme is being developed for primary hyperoxaluria. The company is co-founded by CRISPR pioneer Feng Zhang and has established multiple collaborations, including but not limited to Vertex Pharmaceuticals and Vor Biopharma.


HashtagArbor Biotechnologies

Company: Arbor Biotechnologies
Search CRISPR Medicine